Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) -- Ignore unavailable to you. Want to Upgrade?

To: I_Banker who wrote (339)	1/14/2005 1:35:58 AM
From: idahoranch1	Respond to of 371

I don't believe it was, Zevalin and BEXXAR are both there for that as the radioactive isotopes they are conjugated with give them a lot more potency than a naked antibody. While they have more power to kill the malignant cells, the downside is that not all the isotopes stay bound to the antibody and some of it can get into the bone marrow creating new issues that aren't wanted. The downside of getting E-mab approved in NHL is that you have to show you are reasonable safe and better than the standard of care. However, in autoimmune disease, all you have to show is that the drug is safe and has efficacy. Throw in that lupus has unmet need and it becomes the logical route to approval.